KRAS and familial pancreatic carcinoma: Inhibiting the expression of KRAS G12C induces sustained activation of FAK, subsequently restoring the vitality of KRAS G12C mutant tumor cells, including a human CRC cell line (SW837), a human Pancreatic cancer cell line (Mia PaCa-2), and 3 human NSCLC cell lines (NCI-H23, NCI-H1792, and NCI-H2122), through the FAK/YAP pathway (Zhang L et al., 2021).